This pioneering work by the two groups led to clinical trials based on the use of antibodies against the two immunoinhibitory receptors CTLA-4 and PD-1 which resulted in successful cancer immunotherapy, especially after PD-1 blockade, and combined blockade of the PD-1 and CTLA-4 (7, 8). This evidence concerns the gene CTLA4 and cancer.